“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, Baltimore, February 17, 2015: Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon)
announced today that they have entered into a definitive agreement under which the companies will jointly
develop fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline’s
Advair Diskus®. Lupin will be responsible for commercialization of the product. Celon will supply the product to
Lupin for its commercialization in the United States, Canada, Mexico, and other key markets. GlaxoSmithKline’s
Advair Diskus® had global sales of over USD 7 billion as of last fiscal.
Lupin CEO Vinita Gupta said, “This collaboration is an important milestone in Lupin’s efforts to evolve its global
inhalation pipeline. We are very pleased to partner with Celon given their experience in the development and
manufacturing of fluticasone/salmeterol DPI in Europe. This coupled with Lupin’s expertise in inhalation product
development and commercialization in the US and other markets will accelerate the development of generic
Advair Diskus® for global markets. We look forward to providing access to high quality, affordable
fluticasone/salmeterol DPI as part of our strategy to deliver inhaled products to key markets’
Celon’s CEO and Managing Director Maciej Wieczorek, Ph.D. said, “Our scientific and technical teams look
forward to collaborating with Lupin to bring this product to major markets outside of Poland. We are
enthusiastic and believe that both the companies would work together to complete a time bound research and
development program to ensure successful registration in targeted markets, for Lupin to effectively
commercialize the product.”
Celon Pharma is a dynamically developing Polish biopharmaceutical company with a strong research and
marketing orientation. Celon Pharma is a leader in research and development that enables the creation of a
broad new class of human therapeutics. Celon has built a platform to develop a wide pipeline of drug products
to treat a vast array of important diseases. Celon invests in development of effective and innovative original
drugs, which can be used in therapies of cancer, neurological disorders, diabetes and other metabolic disorders.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of
branded and generic formulations as well as biotechnology products and APIs globally. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space
and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions,
IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top
10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014,
Lupin's Consolidated revenues and Profit after tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364
million (USD 304 million) respectively. Please visit http://www.lupin.com for more information.
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.
About Lupin Pharmaceuticals Inc.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality,
affordable generic medicines and branded formulations trusted by healthcare professionals and patients across
geographies. For more information, please do visit http://www.lupinpharmaceuticals.com
You could also follow us on Twitter – www.twitter.com/lupinlimited
For more information, please contact –
Head – Corporate Communications
Ph: +91-22- 98 20 338 555
Head – M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement